Misaki T, Watanabe G, Iwa T, Watanabe Y, Mukai K, Takahashi M, Ohtake H, Yamamoto K
Department of Surgery (1), Toyama Medical and Pharmaceutical University, Japan.
J Thorac Cardiovasc Surg. 1995 Dec;110(6):1702-7. doi: 10.1016/S0022-5223(95)70034-X.
Ebstein"s anomaly is the most common congenital heart disease associated with the Wolf-Parkinson-White syndrome. Between November 1973 and March 1993, we surgically treated 42 patients with Wolff-Parkinson-White syndrome and Ebstein's anomaly. The patient's ages ranged from 5 months to 59 years (mean 35.3 +/- 14.0 years). There were a total of 52 accessory pathways, 48 of which were located in the right (65%) or posteroseptal (29%) area. A left-sided accessory pathway was seen in only two patients (3.8%). Division of all right-sided accessory pathways was done during normothermic cardiopulmonary bypass with the heart beating; cryocoagulation was applied together with scalpel dissection of the atrioventricular groove. Division of the left-sided accessory pathways was done with the use cold potassium cardioplegic arrest. Thirty-five of these patients underwent tricuspid valve operation for Ebstein's anomaly and 11 of them underwent tricuspid valve replacement with a bioprosthesis. All 52 accessory pathways were successfully divided, although two patients required reoperation because of tachycardia caused by accessory pathways in different positions. Three hospital deaths (7.1%) occurred. There were no late deaths during the follow-up period (mean 94.3 +/- 52.4 months), but two patients required repeat tricuspid operation because of progression of the tricuspid regurgitation. Because no repeat operations were required during long-term follow-up patients who underwent valve repair or valve replacement, correction should be indicated in some patients.
埃布斯坦畸形是与预激综合征相关的最常见先天性心脏病。1973年11月至1993年3月期间,我们对42例患有预激综合征和埃布斯坦畸形的患者进行了外科治疗。患者年龄从5个月至59岁不等(平均35.3±14.0岁)。共有52条附加通路,其中48条位于右侧(65%)或后间隔(29%)区域。仅在2例患者(3.8%)中发现左侧附加通路。所有右侧附加通路均在心脏跳动的常温体外循环期间进行切断;在进行房室沟的手术刀解剖时同时应用冷冻凝固。左侧附加通路的切断在冷钾停搏液灌注下进行。其中35例患者因埃布斯坦畸形接受了三尖瓣手术,11例患者接受了生物假体三尖瓣置换术。所有52条附加通路均成功切断,尽管有2例患者因不同位置的附加通路导致心动过速而需要再次手术。发生了3例医院死亡(7.1%)。随访期间(平均94.3±52.4个月)无晚期死亡,但有2例患者因三尖瓣反流进展需要再次进行三尖瓣手术。由于接受瓣膜修复或瓣膜置换的患者在长期随访期间无需再次手术,因此在某些患者中应考虑进行矫正。